ReShape Lifesciences Files 8-K

Ticker: HIND · Form: 8-K · Filed: Dec 11, 2024 · CIK: 1427570

Reshape Lifesciences Inc. 8-K Filing Summary
FieldDetail
CompanyReshape Lifesciences Inc. (HIND)
Form Type8-K
Filed DateDec 11, 2024
Risk Levellow
Pages6
Reading Time7 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure

TL;DR

ReShape Lifesciences filed an 8-K on 12/11/24, likely containing important company updates.

AI Summary

On December 11, 2024, ReShape Lifesciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates that ReShape Lifesciences Inc. is providing updates or disclosures to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report without immediate indication of significant negative events.

Key Players & Entities

  • ReShape Lifesciences Inc. (company) — Registrant
  • December 11, 2024 (date) — Date of earliest event reported
  • 18 Technology Drive, Suite 110, Irvine, CA 92618 (address) — Principal executive offices
  • 949-429-6680 (phone_number) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing for ReShape Lifesciences Inc.?

The filing is for Regulation FD Disclosure and Financial Statements and Exhibits, as indicated in the report.

On what date was the earliest event reported in this 8-K filing?

The earliest event reported was on December 11, 2024.

What is the principal executive office address for ReShape Lifesciences Inc.?

The principal executive offices are located at 18 Technology Drive, Suite 110, Irvine, CA 92618.

What is the telephone number for ReShape Lifesciences Inc.?

The registrant's telephone number is (949) 429-6680.

What is the former name of ReShape Lifesciences Inc.?

The former name of the company was OBALON THERAPEUTICS INC, with a date of name change on 20080220.

Filing Stats: 1,700 words · 7 min read · ~6 pages · Grade level 14.1 · Accepted 2024-12-11 08:29:12

Key Financial Figures

  • $0.001 — nge on which Registered Common stock, $0.001 par value per share RSLS The Nasdaq C

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Representatives of ReShape Lifesciences Inc. (the "Company") and Vyome Therapeutics, Inc. intend to make presentations at investor conferences and in other forums and these presentations may include the information contained in Exhibit 99.1 attached to this Current Report on Form 8-K. A copy of the presentation slides containing such information that may be disclosed by the Company is attached as Exhibit 99.1 to this report and the information set forth therein is incorporated herein by reference and constitutes a part of this report. The Company is furnishing the information contained in Exhibit 99.1 pursuant to Regulation FD and Item 7.01 of Form 8-K promulgated by the Securities and Exchange Commission ("SEC"). This information shall not be deemed to be "filed" with the SEC for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The information contained in Exhibit 99.1 is summary information that is intended to be considered in the context of the Company's SEC filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in Exhibit 99.1, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure. By filing this report and furnishing this information, the Company makes no admission as to the materiality of any information contained in this report, including Exhibit 99.1. Additional Information In

Forward-Looking Statements

Forward-Looking Statements Certain statements contained in this filing may be considered forward-looking Sale and the ability to consummate the Merger and Asset Sale. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "believes," "plans," "anticipates," "projects," "estimates," "expects," "intends," "strategy," "future," "opportunity," "may," "will," "should," "could," "potential," or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and ReShape undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: (1) ReShape may be unable to obtain stockholder approval as required for the proposed Merger and Asset Sale; (2) conditions to the closing of the Merger or Asset Sale may not be satisfied; (3) the Merger and Asset Sale may involve unexpected costs, liabilities or delays; (4) ReShape's business may suffer as a result of uncertainty surrounding the Merger and Asset Sale; (5) the outcome of any legal proceedings related to the Merger or Asset Sale; (6) ReShape may be adversely affected by other economic, business, and/or competitive factors; (7) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement or Asset Purchase Agreement; (8) the effect of the announcement of the Merger and Asset Purchase Agreement on the ability of R

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description Method of Filing 99.1 Investor Presentation Slides Furnished herewith 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENTEROMEDICS INC. By: /s/ Paul F. Hickey Paul F. Hickey Chief Executive Officer Dated: December 11, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.